Renovion’s ARINA-1 Receives Fast Track Designation from FDA for Prevention of BOS Progression in Bilateral Lung Transplant Patients
Renovion, Inc. has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ARINA-1, a medicine developed for the prevention of bronchiolitis obliterans syndrome (BOS) prog ...